Prof. Mayra Ramos-Suzarte

Center of Molecular Immunology, Cuba

Professor

Email: mayra@cim.sld.cu

Qualifications

2002 Ph.D., National Medical University, Cuba

1987 B.Sc., Havana University, Cuba

Publications (Selected)

1. Niurys de Castro-Suárez, Mirjam N. Trame, Mayra Ramos-Suzarte, José M. Dávalos, Raymed A. Bacallao-Mendez, Anaelys R. Maceo-Sinabele, Víctor Mangas-Sanjuán, Gledys Reynaldo-Fernández and Leyanis Rodríguez-Vera. Semi-mechanistic pharmacokinetic model to guide the dose selection of nimotuzumab in patients with autosomal dominant polycystic kidney disease. Pharmaceutics 2020, 12.
2. Leyanis Rodríguez Vera1Gledys Reynaldo Fernández, Eduardo M. Fernández-Sánchez, Mayra Ramos Suzarte, Daniel Amaro, Roberto Menéndez, Helena Colom, Víctor Mangas-Sanjuan, Gilberto Castañeda Jorge Duconge, Braulio Jiménez-Vélez, Niurys de Castro Suárez Carmen Viada, Joaquín Solazábal, María de los A. Bécquer. Aporte farmacométrico en el desarrollo de productos biotecnológicos. cubanosAnales de la Academia de Ciencias de Cuba; Vol. 10, No. 3 (2020).
3. Armando Caballero1, L_azaro M Filgueira, Julio Betancourt, Naivy Sanchez, Carlos Hidalgo,Alberto Ramırez, Alejandro Martinez, Rolando E Despaigne, Alberto Escalona, Henrry Diaz, Elio Merino, Lilia M Ortega, Ulises Castillo, Mayra Ramos, Danay Saavedra, Yanelda Garcıa, Geydi Lorenzo, Meylan Cepeda, Mayren Arencibia, Leticia Cabrera, Milagros Domecq,Daymys Estevez, Carmen Valenzuela, Patricia Lorenzo, Lizet Sanchez, Zaima Mazorra, Kalet Leon & Tania Crombet (2020). Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab. Clinical & Translational Immunology, 9 (11), e1218, doi:10.1002/cti2.1218.
4. Danay Saavedra, Ana Laura Añé-Kourí, Naivy Sánchez, Lázaro Manuel Filgueira, Julio Betancourt, Carlos Herrera, Leniel Manso, Elibet Chávez, Armando Caballero, Carlos Hidalgo, Geydi Lorenzo, Meylan Cepeda, Carmen Valenzuela, Mayra Ramos, Kalet León, Zaima Mazorra, Tania Crombet. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. 2020. Immunity & Ageing (2020) 17:34. https://doi.org/10.1186/s12979-020-00207-8
5. Yayquier Díaz, Mayra Ramos-Suzarte, Yordanis Martín, Néstor Antonio Calderón, William Santiago, Orlando Viñet, Yulieski La O, Jorge Pérez Augusto Oyarzábal, Yoan Pérez, Geidy Lorenzo, Meylan Cepeda, Danay Saavedra, Zaima Mazorra, Daymys Estevez, Patricia Lorenzo-Luaces, Carmen Valenzuela, Armando Caballero, Kalet Leon, Tania Crombet, Carlos Jorge Hidalgo. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. 2020 Gerontology. Oct 26: 1-9. doi: 10.1159/000512210, PMCID: PMC7649683
6. Aliz M Vega, Lisandro Vila, Pedro Venereo, Ana R Valls, Esther L De Armas, Maria A Romero, Alcides Ruiz, Carmen E Viada, Patricia Piedra, Giselle Saurez1, Yisel Avila7, Clara M Cuesta7, Amparo Macías1,Tania Crombet and Mayra Ramos Suzarte Safety and Effectiveness of Nimotuzumab in the Treatment of Advanced Head and Neck Cancer Patients. Phase IV Clinical Trial: Final Results. JJ Cancer Sci Res 2019; 4(1): 057.
7. Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Review. PMID: 30318080
8. Shuping Xu, Mayra Ramos Suzarte, Xianhong Bai, Binghe Xu. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget, Advance Publications. March 31, 2016.
9. Lucely Cetina, Tania Crombet, Roberto Jiménez-Lima, Sergio Zapata, Mayra Ramos, Sandra Avila, Jaime Coronel, Eduardo Charco, Rafael Bojalil, Horacio Astudillo, Blanca Bazán, Alfonso Dueñas-González. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.Cancer biology & therapy 03/2015; 24. DOI:10.1080/15384047.2015.1026483
10. Leyanis Rodríguez-Vera, Mayra Ramos Suzarte, Eduardo Fernández-Sánchez, Jorge Luis Soriano, Concepción Peraire Guitart, Gilberto Castañeda Hernández, Carlos Orlando Jacobo Cabral, Niurys de Castro Suárez, Helena Colom Codina Semi-Mechanistic Model to Characterize Non-Linear Pharmacokinetic of Nimotuzumab in Patients with Advanced Breast Cancer. The Journal of Clinical Pharmacology 03/2015; DOI:10.1002/jcph.496
11. U Pérez González, F F Llorente Llano, M Ramos Suzarte, J E Rodríguez Reigosa, B F Mestre Fernández, M Osorio Rodríguez, E A Gracia Medina, M R Orellana Alvarado, I Leonard Feliú, Y T Ojeda Abizaid, J Alert Silva, A M Ulloa Balmaseda, N Y González Barallobre, E Galá Barrios, N Curbelo Sevillano, R B Jiménez García, B B Brunet Flores, M Cedeño Arias, R Blanco Santana: gastrointestinal tumours, colorectal 614tip double-blind, placebo-controlled, multicenter, randomized, phase ii study of nimotuzumab in combination with mitomycin, 5-fluorouracil and radiation in immunocompetent patients with anal carcinoma. Annals of Oncology 09/2014; 25 suplement 4.
12. Mayra Ramos Suzarte, Juan Perfecto Oliva, Nelson Rodriguez Mesa. Inmunogammagrafía con los AcM ior-c5 e ior-cea1 en cáncer colorrectal.Tumores Primarios, Metástasis y Recidivas. Editorial EAA. Libro. ISBN: 978-3-659-07006-8. Mayo 2013.
13. Rancés Blanco, Charles E. Rengifo, Mercedes Cedeño, Milagros Frómeta, Enrique Rengifo, Mayra Ramos-Suzarte: Tumor Expression of the Carcinoembryonic Antigen Correlates with High Mitotic Activity and Cell Pleomorphism Index in Lung Carcinoma. Journal of Histology. 05/2013; Volume 2013 (2013), (Article ID 827089): 8 pages.
14. Mayra Ramos Suzarte, Juan Perfecto Oliva, Nelson Rodriguez Mesa. Inmunogammagrafía con los AcM ior-c5 e ior-cea1 en cáncer colorrectal. Tumores Primarios, Metástasis y Recidivas. Editorial EAA. Libro. ISBN: 978-3-659-07006-8. Mayo 2013.
15. Leyanis Rodriguez Vera, Eduardo fernandez Sanchez, Jorge luis Soriano, Noide Batista, Mayte Lima, Joaquin Gonzalez, Robin Garcia, Carmen Viada, Concepcion peraire, Elena Colom, and Mayra Ramos-Suzarte. “Pharmacokinetics Evaluation of Nimotuzumab in Combination with Doxorrubicin and Ciclophosphamide in Patients with Advanced Breast Cancer". Life Science 10/2013; DOI: ISSN 1934-7391, USA.
16. Pedro C. Rodriguez; Roberto Torres-Moyab, Gil Reyes, Claudino Molinerob, Dinorah Prada, Ana M. Lopezb,Isabel M. Hernandezb, Maria V. Hernandezb, Jose P. Martinezb, Xochel Hernandeza,, Angel Casaco, Mayra Ramos, Yisel Avila, Yinet Barrese, Enrique Montero, Patricia Hernandez. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, inpatients with rheumatoid arthritis. Results in Immunology, 2 (2012) 204-211.